ArticleJournal of gastric cancer2023

Efficacy and Safety of Trastuzumab Deruxtecan and Nivolumab as Third- or Later-Line Treatment for HER2-Positive Advanced Gastric Cancer: A Single-Institution Retrospective Study.

Keitaro Shimozaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.